UPMC HANOVER
1. Target Overview & Investment Thesis
UPMC HANOVER is a 73-bed suburban community hospital in YORK, PA with $200.8M in net patient revenue and a 18.2% operating margin. The hospital serves a payer mix of 39.0% Medicare, 3.4% Medicaid, and 57.7% commercial.
Thesis: Turnaround. Our ML models identify $14.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 18.2% to 25.5% (+736bps).
| Net Revenue HCRIS | $200.8M |
| Current EBITDA COMPUTED | $36.5M |
| Operating Margin COMPUTED | 18.2% |
| Occupancy HCRIS | 87.2% |
| Revenue / Bed COMPUTED | $2.8M |
| Net-to-Gross HCRIS | 30.7% |
| Distress Probability ML | 37.8% |
2. Market Context & Competitive Position
PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 18.2% places it above the state median. Among 99 size-comparable peers (36-146 beds), the median margin is -1.7%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (36-146), prioritizing same-state peers. 99 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| UPMC HANOVER (Target) | PA | 73 | $200.8M | 18.2% |
| THE GETTYSBURG HOSPITAL | PA | 76 | $341.8M | 18.4% |
| ST. JOSEPH MEDICAL CENTER | PA | 132 | $334.8M | 13.2% |
| EPHRATA COMMUNITY HOSPITAL | PA | 115 | $291.8M | 3.8% |
| THE GOOD SAMARITAN HOSPITAL | PA | 145 | $269.5M | -5.0% |
| AMERICAN ONCOLOGIC HOSPIAL | PA | 100 | $229.8M | -11.1% |
| EVANGELICAL COMMUNITY HOSPITAL | PA | 119 | $223.6M | 5.1% |
| ST. LUKES HOSPITAL - MONROE CA | PA | 98 | $221.8M | 7.8% |
| GEISINGER LEWISTOWN HOSPITAL | PA | 107 | $210.8M | 11.2% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $14.8M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $4.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $4.0M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $4.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.4M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $128K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $36.5M |
| + RCM Uplift | +$14.8M |
| Pro Forma EBITDA | $51.2M |
| Current Margin | 18.2% |
| Pro Forma Margin | 25.5% |
| WC Released (1x) | $7.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $56.1M | $388.2M | 6.92x | 47.2% |
| Base (11x exit) | 10.0x | 11.0x | $56.1M | $445.3M | 7.94x | 51.3% |
| Bull Case | 9.0x | 11.0x | $50.5M | $512.3M | 10.15x | 59.0% |
| Bull (12x exit) | 9.0x | 12.0x | $50.5M | $573.7M | 11.37x | 62.6% |
| Bear Case | 11.0x | 10.0x | $61.7M | $296.1M | 4.80x | 36.9% |
| Bear (11x exit) | 11.0x | 11.0x | $61.7M | $345.8M | 5.61x | 41.2% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 99 hospitals with 36-146 beds
- Same-state prioritization (n=100)
- Comp margins: P25=-18.5% / P50=-1.7% / P75=8.5%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.